Scholarlink

<p>Depression is a major cause of disability worldwide, motivating interest in psilocybin as a potential treatment. Here we present a living systematic review and open-data meta-analytic resource on psilocybin treatment for depressive symptoms. In this initial release, 15 randomized controlled trials comprising 801 participants are included in the database, with 12 of those studies included in our primary model (<i>n</i> = 585) using inverse-variance random-effects modeling of standardized mean differences on primary outcomes. Compared with control conditions, psilocybin showed a greater reduction in depression scores (Hedges’ <i>g</i> = −0.90). This systematic review and meta-analysis suggests that psilocybin-assisted therapy results in substantial decreases in depressive symptoms across studies to date. However, many studies have small sample sizes or risk of bias. This living systematic review, meta-analysis, database and online dashboard (<a href="http://sypres.io">sypres.io</a>) will continue to be updated as evidence emerges, providing a valuable resource for researchers in a rapidly evolving field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression

  • 期刊论文

  • 发表日期：

    2026年4月6日

查看全文
  • S. Parker Singleton,
  • Brooke L. Sevchik,
  • Analiese Lahey,
  • Pim Cuijpers,
  • Mathias Harrer,
  • Megan T. Jones,
  • Sandeep M. Nayak,
  • Eric C. Strain,
  • Simon N. Vandekar,
  • Robert H. Dworkin,
  • J. Cobb Scott,
  • Theodore D. Satterthwaite

摘要

Depression is a major cause of disability worldwide, motivating interest in psilocybin as a potential treatment. Here we present a living systematic review and open-data meta-analytic resource on psilocybin treatment for depressive symptoms. In this initial release, 15 randomized controlled trials comprising 801 participants are included in the database, with 12 of those studies included in our primary model (n = 585) using inverse-variance random-effects modeling of standardized mean differences on primary outcomes. Compared with control conditions, psilocybin showed a greater reduction in depression scores (Hedges’ g = −0.90). This systematic review and meta-analysis suggests that psilocybin-assisted therapy results in substantial decreases in depressive symptoms across studies to date. However, many studies have small sample sizes or risk of bias. This living systematic review, meta-analysis, database and online dashboard (sypres.io) will continue to be updated as evidence emerges, providing a valuable resource for researchers in a rapidly evolving field.